Clario

Clario is a business unit of Thermo Fisher Scientific, a publicly traded life sciences company. The firm presents itself as 'part of Thermo Fisher Scientific' on its website and corporate materials.

Clario offers a broad endpoint technology platform that includes cardiac safety (ECG, blood pressure monitoring, arrhythmia analysis), electronic clinical outcome assessments (eCOA), medical imaging (CT, MRI, endoscopy with AI redaction), precision motion (wearable sensors for mobility endpoints), and respiratory solutions (spirometry, cough and lung sound analysis).

Clario does not raise capital from external LPs for investment; it is a business-to-business clinical services provider. Client relationships typically come through pharmaceutical companies, biotechs, and contract research organizations that require endpoint data collection for clinical trials.

Clario covers cardiovascular and metabolic, dermatology, diabetes and obesity, gastroenterology, hepatology, infectious diseases, musculoskeletal, neuroscience (dementias, headache disorders, movement disorders, multiple sclerosis, pain, psychiatric), oncology, ophthalmology, and respiratory.

Yes, Clario deploys AI in several areas, notably its Image Redact AI tool that automatically redacts patient identifiers from medical images, videos, and PDFs. The firm also uses AI in respiratory data interpretation and across its imaging platform.